Skip to Main Content

REF2HCT: Haploidentical Bone Marrow Transplant for Relapsed or Refractory Leukemia, Lymphoma, or Myelodysplastic Syndrome After an Earlier Transplant

About this study

Cancers like leukemia and lymphoma are often treated with chemotherapy. Sometimes, the cancer comes back, or relapses, after treatment. In other cases, the cancer does not improve after treatment.

Doctors may treat tough cancers like these with a bone marrow transplant, also called a hematopoietic (blood) cell transplant. The procedure begins with chemotherapy (strong cancer medicine) to kill the patient’s bone marrow and make room for the transplanted cells. Next, doctors remove cells from a donor and inject them into the patient. These donor blood cells grow in the patient and make new blood cells to fight the cancer.

The best donor for this type of transplant is a brother or sister who matches the patient’s immune type. If the patient does not have a brother or sister who is a suitable donor, another donor may be used. Other donors may include someone who is not related to the patient or a family member who is only a partial match.

This clinical trial will treat patients whose cancer has come back or worsened despite having a previous bone marrow transplant. In this St. Jude study, doctors will perform a new bone marrow transplant using donor cells from a family member who is a partial match for the patient’s immune type. This type of transplant is called a haploidentical transplant.

Eligibility overview

  • 21 years old and younger
  • Diagnosed with one of the following that has come back after a previous bone marrow transplant or did not improve after bone marrow transplant
    • Acute lymphoblastic leukemia (ALL)
    • Acute myeloid leukemia
    • Myeloid sarcoma
    • Chronic myeloid leukemia (CML)
    • Juvenile myelomonocytic leukemia (JMML)
    • Myelodysplastic syndrome (MDS)
    • Non-Hodgkin lymphoma (NHL)
  • Has a family member who is a suitable stem cell donor

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation

Study goal:

The main goal of this study is to learn about the good and bad effects of transplanting blood cells donated by a family member to children and young adults with cancer that has come back or did not improve after a previous bone marrow transplant.


Leukemia, Lymphoma, Myeloid sarcoma, Myelodysplastic syndrome, Juvenile Myelomonocytic Leukemia, Non-Hodgkin Lymphoma


21 years old and younger

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more